Large B-cell Lymphoma
Conditions
Interventions
In this imaging trial, the purpose is to explore the feasibility of anti-CD8 PET imaging to gain insights into the biodistribution of CD8+ T-cell before and after CD19-directed CAR T-cell therapy in R
Sponsors
UMCG
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects with histologically confirmed LBCL and subtypes according to the WHO 2016 criteria 2. who fulfill the eligibility criteria for anti-CD19 CAR T-cell therapy according the Immune Effector Cell Working Group Tumorboard. 3. Tumor lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures. 4. Measurable disease, as defined by Lugano criteria. 5. Signed informed consent. 6. Age =18 at the time of signing informed consent. 7. Life expectancy =12 weeks. 8. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 9. Ability to comply with the protocol. 10. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly).
Exclusion criteria
Exclusion criteria: 1. Signs or symptoms of active infection within 2 weeks prior to ZED88082A/CED88004S injection, unless treated to resolution. 2. Prior CD19-directed CAR T-cell therapy or other bi-specific antibodies targeting CD19 receptor (e.g. blinatumomab). 3. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. 4. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ZED88082A/CED88004S, or that may affect the interpretation of the results or render the patient at high risk from complications. 5. Pregnant or lactating women. 6. HIV-positive patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - To determine the whole-body biodistribution of the ZED88082A tracer in normal tissues and tumor lesions before and after CAR T-cell therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Assess safety and dosimetry ZED88082A/CED88004S uptake in the setting of CD19-directed CAR T-cell therapy - Correlative expression analysis between ZED88082A tracer standard uptake volume (SUV) parameters in the tumor, CD8 expression in tumor biopsy, and response to CAR T-cell therapy. - To perform correlative expression analysis between SUV parameters of ZED88082A tracer in the tumor, CD8 expression in tumor biopsy, and SUV parameters in the tumor and whole-body and CAR T-cell persistence, peak level and CAR T-cell phenotype as measured in the peripheral blood. - Correlative expression analysis between ZED88082A tracer SUV parameters in the tumor, and grade 1-5 adverse events to CAR T-cell therapy, including cytokine release syndrome and neurotoxicity. - Correlative expression analysis between ZED88082A tracer uptake in irradiated versus non-irradiated lymphoma lesions in patients who require radiotherapy as bridging strategy prior to CAR T-cell infusion. | — |
Contacts
Public ContactMargriet Dijkstra
UMCG
Outcome results
None listed